# How Should Healthcare Organizations Perform AI Vendor Diligence?

Lily Armstrong · October 19, 2026

> Verify Privacy and Security Claims Healthcare organizations should evaluate AI vendors as critical third-party technology providers, not simply as...

## Verify Privacy and Security Claims

Healthcare organizations should evaluate AI vendors as critical third-party technology providers, not simply as software sellers. “HIPAA compliant” is not a government certification, so vendors should explain exactly how protected health information is processed, stored, transmitted, and deleted. Diligence should examine security controls, encryption, access management, audit logs, breach-notification duties, business continuity plans, and the vendor’s compliance history. As Fisher Phillips advises, contracts should clearly allocate responsibility for data use, regulatory compliance, incident response, subcontractors, and remediation. Healthcare CFOs should also ask whether the system supports clinical decisions without exposing patients or clinicians to unsafe outputs.

**Also worth reading:** [What Is the Real ROI of AI Clinical Documentation Review for Healthcare Organizations?](https://healtho.io/knowledge/what_is_the_real_roi_of_ai_clinical_documentation_review_for_healthcare_organizations.php) · [What Are Agentic Healthcare AI Controls, and How Should Health Organizations Use Them in 2026?](https://healtho.io/knowledge/what_are_agentic_healthcare_ai_controls_and_how_should_health_organizations_use_them_in_2026.php) · [How Can Healthcare Leaders Assess AI Vendor Risk Before Deployment?](https://healtho.io/knowledge/how_can_healthcare_leaders_assess_ai_vendor_risk_before_deployment.php)

The review should extend beyond the immediate product. Health systems need to understand downstream risks, including data leakage, model bias, compromised credentials, vendor concentration, and integration with other suppliers. Reports from HSCC and MedCity News emphasize that AI-driven supply chains can develop faster than existing cybersecurity oversight. Organizations should therefore require evidence, test controls, review independent assessments, and establish ongoing monitoring rather than relying on questionnaires alone. Emerging legislation and governance proposals, including the framework discussed by Quarles, reinforce the need for accountable executive ownership. A healthcare benefits consultant can help connect these legal, clinical, financial, and operational considerations without treating unsupported compliance language as proof of safety.

## Assess Clinical and Operational Safety

Healthcare organizations should treat AI vendor diligence as an enterprise risk assessment, not a sales checklist. Before contracting, they should verify HIPAA safeguards, data residency, encryption, access controls, breach notification, retention, and deletion practices, and whether “HIPAA compliant” is a certification rather than a vendor’s self-attestation. The Fisher Phillips analysis is relevant because overstatement can create compliance exposure without establishing that a product meets HIPAA requirements. Security and operational teams should test identity management, model permissions, integration points, downtime procedures, and whether subcontractors introduce hidden risks.

Healthcare leaders should add contractual protections for audit rights, incident timelines, data-use restrictions, model transparency, performance monitoring, and termination assistance. The MedCity questions and Quarles governance framework provide starting points, while HSCC’s warning that AI-enabled supply chains are outpacing defenses argues for continuous oversight. Procurement should involve compliance, security, clinical, IT, legal, and finance leaders with defined ownership and escalation paths. Diligence should compare promised benefits with measurable clinical outcomes, workflow impact, human oversight, and total cost of ownership, ensuring the platform creates safer care and sustainable operations, not merely attractive technology.

## Evaluate Bias and Transparency

Healthcare organizations should treat AI vendor diligence as an ongoing governance process, not a one-time security checklist. Before contracting, they should assess bias and transparency by examining training-data representativeness, documented validation across relevant patient populations, explainability, error reporting, and mechanisms for human review. A vendor’s claim of “HIPAA compliance” does not prove that its entire product, subprocessors, or deployment practices are compliant. Organizations must also evaluate cybersecurity controls, breach responsibilities, data ownership, model updates, monitoring, incident response, and regulatory compliance. Contracts should specify performance metrics, audit rights, indemnification, and remedies for unsafe outputs.

Diligence should continue after implementation through independent testing, drift and bias monitoring, complaint review, and periodic reassessments. Healthcare leaders should involve clinical, legal, privacy, security, finance, and procurement teams, while frontline users help identify workflow risks and unintended consequences. Transparency also requires clear communication about AI use and its limitations. Ultimately, accountability cannot be outsourced to the vendor: healthcare organizations remain responsible for decisions that affect patients and must be able to explain, challenge, and correct AI-generated outcomes.

## Review Data and Contractual Protections

Healthcare organizations should evaluate AI vendors as critical technology suppliers, not simply software providers. Diligence should examine security controls, access management, encryption, incident response, disaster recovery, data retention, and whether the vendor can comply with HIPAA and applicable state privacy laws. “HIPAA compliant” is not an independent certification, so organizations should request supporting evidence, audit results, penetration-test summaries, and a signed business associate agreement where protected health information is involved. They should also assess clinical validation, bias and safety testing, data provenance, model-update practices, performance monitoring, and the vendor’s ability to support investigations or regulatory inquiries.

Contractual protections should translate these expectations into enforceable obligations. Agreements should define permitted data uses, prohibit training on customer data without consent, require prompt breach notification, establish security standards, and provide audit and compliance reporting rights. Healthcare organizations should also negotiate indemnification, limitations of liability, intellectual property rights, subcontractor controls, service-level commitments, transition assistance, and termination rights. Given fast-changing AI risks, contracts should include periodic reassessment and a right to suspend or terminate the service if the vendor materially fails to meet legal, clinical, or security requirements.

## Plan Ongoing Vendor Oversight

Healthcare organizations should treat AI vendor diligence as continuous risk management, not a one-time security questionnaire. As Fisher Phillips emphasizes, “HIPAA compliant” is not a certification, so providers should request evidence supporting specific claims, including data-flow diagrams, encryption practices, access controls, audit logs, incident-response procedures, and subcontractor oversight. Vendors should also explain how they use protected health information, whether they train models with it, where data is stored, and how long it is retained. Independent assessments, customer references, breach history, and regulatory records can help distinguish verified safeguards from marketing language.

Oversight must continue throughout the contract relationship. Healthcare systems should assign accountable executives, monitor model performance and bias, review access and security events, and establish escalation and termination rights. MedCity News suggests asking seven essential contracting questions, while emerging legislation, including the framework discussed by Quarles, may shape additional governance duties. HSCC further warns that AI-enabled supply chains can evolve faster than healthcare oversight models. Organizations should therefore inventory every vendor and downstream dependency, require transparent reporting, conduct periodic reassessments, and incorporate contractual remedies. Advice from a specialist such as healtho.io can support this structured, risk-based approach.

## AI Vendor Diligence Comparison

| Diligence Area | Key Questions to Ask | Evidence and Red Flags |
| --- | --- | --- |
| Compliance and Governance | Does “HIPAA compliant” mean the vendor supports a customer’s compliance obligations? Who oversees AI governance, security, clinical validation, and regulatory reporting? | Marketing claims without independent assessments, outdated policies, unclear accountability, or no documented governance processes. |
| Data, Security, and Subprocessors | What data is collected, used, retained, or shared? Where is it stored, and which subprocessors can access it? | Missing encryption, access controls, audit logs, data-location details, business associate agreements, or complete subprocessor disclosures. |
| Performance and Patient Safety | How were the model’s accuracy, bias, reliability, and clinical outcomes validated? What monitoring occurs after deployment? | Weak validation, biased testing, unexplained performance claims, no human-oversight plan, or no strategy for model drift. |
| Contractual and Operational Resilience | What incident-notification, audit, indemnification, service-level, breach-cost, and termination rights apply? | Liability caps, limited notification periods, automatic renewals, proprietary restrictions, or no transition assistance for data and workflows. |

Healthcare organizations should treat AI vendor diligence as an enterprise risk process, not a checkbox. “HIPAA compliant” is not a certification, so contracts should define data use, security controls, incident duties, subcontractor accountability, and audit rights. Claims should be tested against evidence, reference customers, regulatory history, and independent assessments. Governance, clinical validation, and continuous monitoring should continue throughout the relationship, with contractual remedies.

## Quick answers

### Does HIPAA compliance guarantee an AI vendor is safe?

HIPAA compliance addresses specific privacy and security obligations but does not certify the accuracy, fairness, or clinical safety of an AI system.

### What should healthcare organizations request during AI vendor diligence?

Organizations should request audit materials, risk assessments, validation results, incident procedures, and evidence supporting vendor security and compliance claims.

### How can buyers assess algorithmic bias in healthcare AI?

Buyers should examine representative validation data, subgroup performance, documented bias tests, and whether the vendor addresses identified disparities.

### What contract protections should healthcare AI agreements include?

Agreements should allocate responsibilities for data use, security incidents, regulatory cooperation, audit rights, indemnification, and safe system transitions.

Canonical: https://healtho.io/knowledge/how_should_healthcare_organizations_perform_ai_vendor_diligence.php
Markdown: https://healtho.io/knowledge/how_should_healthcare_organizations_perform_ai_vendor_diligence.php/index.md